Defence Therapeutics Granted CNRI-H from the Canadian Nuclear Laboratories to Accelerate the Development of Its Radio-Immuno-Conjugates Program
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) has been approved for the Canadian Nuclear Research Initiative Health (CNRI-H) Program by Canadian Nuclear Laboratories (CNL). This collaboration aims to accelerate Defence's radio-immuno-conjugates project, focusing on novel 111In-AccuTOX®-Trastuzumab constructs.
The project's objectives include:
- Synthesizing and evaluating constructs to demonstrate AccuTOX®'s role in evading endosome entrapment
- Ensuring nuclear localization for 111In to emit Auger Electrons
- Developing constructs lethal to HER2-positive cancer cells
- Identifying a potent 111In-AccuTOX®-Trastuzumab molecule for treating solid tumors resistant to current HER2-targeting therapies
The global radiopharmaceuticals market is projected to reach $21.8 billion by 2033, with a CAGR of 10.6% from 2024 to 2033.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) ha ricevuto l'approvazione per il Programma Health (CNRI-H) dell'Iniziativa Canadese di Ricerca Nucleare da parte dei Canadian Nuclear Laboratories (CNL). Questa collaborazione ha l'obiettivo di accelerare il progetto di radio-immuno-coniugati di Defence, concentrandosi su nuovi costrutti di 111In-AccuTOX®-Trastuzumab.
Gli obiettivi del progetto includono:
- La sintesi e la valutazione di costrutti per dimostrare il ruolo di AccuTOX® nell'evitare la cattura negli endosomi
- Garantire la localizzazione nucleare per 111In affinché emetta elettroni Auger
- Sviluppare costrutti letali per le cellule tumorali positive al HER2
- Identificare una potente molecola di 111In-AccuTOX®-Trastuzumab per il trattamento di tumori solidi resistenti alle attuali terapie mirate al HER2
Si prevede che il mercato globale dei radiofarmaceutici raggiunga i 21,8 miliardi di dollari entro il 2033, con un CAGR del 10,6% dal 2024 al 2033.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) ha sido aprobada para el Programa de Salud de la Iniciativa Canadiense de Investigación Nuclear (CNRI-H) por parte de Canadian Nuclear Laboratories (CNL). Esta colaboración tiene como objetivo acelerar el proyecto de radio-inmunoconjugados de Defence, enfocándose en nuevos constructos de 111In-AccuTOX®-Trastuzumab.
Los objetivos del proyecto incluyen:
- La síntesis y evaluación de constructos para demostrar el papel de AccuTOX® en la evasión de la captura en endosomas
- Asegurar la localización nuclear para que el 111In emita electrones Auger
- Desarrollar constructos letales para células cancerosas HER2-positivas
- Identificar una potente molécula de 111In-AccuTOX®-Trastuzumab para tratar tumores sólidos resistentes a las terapias actuales dirigidas a HER2
Se proyecta que el mercado global de radiofármacos alcance los 21.8 mil millones de dólares para 2033, con una Tasa de Crecimiento Anual Compuesto (CAGR) del 10.6% de 2024 a 2033.
방어 치료제 주식회사(방어 치료제 Inc.) (CSE: DTC) (OTCQB: DTCFF)가 캐나다 원자력 연구 이니셔티브 건강 프로그램(CNRI-H)으로 캐나다 원자력 연구소(CNL)로부터 승인받았습니다. 이 협력은 방어의 방사 면역 접합체 프로젝트를 가속화하는 것을 목표로 하며, 새로운 111In-AccuTOX®-트라스투주맙 구조물에 중점을 두고 있습니다.
프로젝트의 목표는 다음과 같습니다:
- AccuTOX®의 엔도좀이 포획을 피하는 역할을 보여주기 위해 구조물을 합성하고 평가하기
- 111In이 Auger 전자를 방출할 수 있도록 핵 내 위치 지정 보장하기
- HER2 양성 암 세포에 치명적인 구조물 개발하기
- 현재 HER2 표적 치료에 저항성인 고형tumor 치료를 위한 강력한 111In-AccuTOX®-트라스투주맙 분자 식별하기
전 세계 방사성 의약품 시장은 2033년까지 218억 달러에 이를 것으로 예상되며, 2024년부터 2033년까지의 연평균 성장률(CAGR)은 10.6%입니다.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) a été approuvé pour le programme de santé (CNRI-H) de l'Initiative canadienne de recherche nucléaire par les laboratoires nucléaires canadiens (CNL). Cette collaboration vise à accélérer le projet de radio-immunoconjugués de Defence, en se concentrant sur de nouveaux constructs 111In-AccuTOX®-Trastuzumab.
Les objectifs du projet incluent :
- La synthèse et l'évaluation de constructs pour démontrer le rôle d'AccuTOX® dans l'évasion de la capture par les endosomes
- Assurer la localisation nucléaire pour que le 111In émette des électrons Auger
- Développer des constructs létaux pour les cellules cancéreuses HER2-positives
- Identifier une molécule puissante 111In-AccuTOX®-Trastuzumab pour traiter les tumeurs solides résistantes aux thérapies actuelles ciblant le HER2
Le marché mondial des radio-pharmaceutiques devrait atteindre 21,8 milliards de dollars d'ici 2033, avec un taux de croissance annuel composé (CAGR) de 10,6 % entre 2024 et 2033.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) wurde vom Canadian Nuclear Laboratories (CNL) für das Gesundheitsprogramm der Canadian Nuclear Research Initiative (CNRI-H) genehmigt. Dieses Zusammenarbeiten zielt darauf ab, das Projekt von Defence zur Entwicklung von Radio-Immunokonjugaten zu beschleunigen, wobei der Fokus auf neuartigen 111In-AccuTOX®-Trastuzumab-Konstrukten liegt.
Die Ziele des Projekts umfassen:
- Die Synthese und Evaluierung von Konstrukten zur Demonstration der Rolle von AccuTOX® bei der Umgehung der Endosomeneinfangung
- Sicherstellen der nuklearen Lokalisierung von 111In zur Emission von Auger-Elektronen
- Entwicklung von Konstrukten, die für HER2-positive Krebszellen tödlich sind
- Identifizierung eines potenten 111In-AccuTOX®-Trastuzumab-Moleküls zur Behandlung von soliden Tumoren, die gegen aktuelle HER2-zielgerichtete Therapien resistent sind
Der globale Markt für Radiopharmazeutika wird bis 2033 voraussichtlich 21,8 Milliarden Dollar erreichen, mit einer jährlichen Wachstumsrate (CAGR) von 10,6% von 2024 bis 2033.
- Approval for CNRI-H Program, providing financial support and expertise from Canadian Nuclear Laboratories
- Potential development of more effective treatments for HER2-positive cancers resistant to current therapies
- Collaboration with CNL may accelerate Defence's progress in the growing radiopharmaceuticals field
- Targeting a rapidly expanding market: global radiopharmaceuticals market projected to reach $21.8 billion by 2033
- None.
Vancouver, British Columbia--(Newsfile Corp. - July 24, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its Canadian Nuclear Research Initiative Health ("CNRI-H") Program application was retained and approved by the Canadian Nuclear Laboratories ("CNL") to accelerate Defence's radio-immuno-conjugates project.
Defence's CNRI-H project will focus on the synthesis and evaluation of novel constructs, variations of 111In-AccuTOX®-Trastuzumab. The objective is to demonstrate that AccuTOX® moiety is an essential modification to conventional 111In-Trastuzumab constructs to evade an endosome entrapment and ensure nuclear localization, where 111In will emit Auger Electrons ("AEs") to kill cancer cells, and providing a synergistic effect by unleashing AccuTOX® immune-boosting power. It is expected that these constructs will be lethal to HER2-positive cancer cells specifically and will produce high potency.
Selected AccuTOX® constructs, based on stability, solubility, and biochemical properties, will be conjugated to the trastuzumab antibody, followed by radiolabeled with 111In, and then characterized, in vitro and in vivo, for its efficacy in killing cancer. The main goal is to identify the biologically active 111In-AccuTOX®-Trastuzumab molecule that will be more potent to treat solid tumor resistant to current HER2-targeting therapy such as therapeutic antibodies (e.g., trastuzumab alone) and antibody-drug conjugate (e.g., Kadcyla®).
In summary, the aim of this CNRI-H collaborative project is:
1. To synthesize AccuTOX®-Trastuzumab antibody conjugates, radiolabel with 111In, and characterize, including structure and cellular analysis (e.g. identification, drug-antibody ratio, specific activity), stability, and cytotoxic effects, in vitro.
2. To perform animal studies in rodents, in vivo, namely biodistribution, pharmacokinetic profile, and therapeutic potency, using selected 111In-AccuTOX®-Trastuzumab constructs.
"We are proud to have this opportunity to collaborate with the Canadian Nuclear Laboratories and to advancing Defence's radio-immuno-conjugates program for the benefit of the cancer's patients. The CNL scientific team dedicated to our project is very strong and will definitely accelerate and reinforce Defence's strength in this renowned and fast-growing radiopharmaceuticals field," said Sebastien Plouffe, Chief Executive Officer of Defence Therapeutics.
CNRI-H is a program developed by CNL to further the realization of its mission of contributing to the health of Canadians. Through CNRI-H, CNL provides financial support along with its expertise, experience, capabilities and makes this available and accessible to the healthcare community to advance new life saving radiopharmaceutical solutions. CNRI-H is a turnkey solution that integrates both funding and project execution in one award. The goal of the program is to accelerate the optimization of therapeutic isotopes production and the clinical translation of targeted radiopharmaceuticals for the benefit of Canadians whilst increasing the safety and efficacy of therapies that involve radiopharmaceuticals.
According to Allied Market Research, the global radiopharmaceuticals market was valued at
https://www.alliedmarketresearch.com/radiopharmaceuticals-market-A14458
https://straitsresearch.com/report/radioligand-therapy-market
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of vaccine antigens or ADCs inside target cells and favoring their processing and activities. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/217439
FAQ
What is the focus of Defence Therapeutics' CNRI-H project with Canadian Nuclear Laboratories?
How might the CNRI-H approval impact Defence Therapeutics (DTCFF) development of radio-immuno-conjugates?
What is the projected growth of the global radiopharmaceuticals market relevant to Defence Therapeutics (DTCFF)?